Management of Genitourinary Symptoms of Menopause

First-Line Treatment Options

The National Comprehensive Cancer Network recommends topical vaginal estrogen therapy, such as Premarin, as the most effective treatment for genitourinary symptoms of menopause in postmenopausal individuals, effectively treating vaginal dryness, itching, discomfort, and painful intercourse 1, 2
Low-dose intravaginal estrogens can be considered to manage genitourinary symptoms of menopause, including vulvovaginal dryness, dyspareunia, and urinary symptoms of urgency, dysuria, or recurrent urinary tract infections 3, 4

Vaginal moisturizers and lubricants can help alleviate symptoms such as vaginal dryness and sexual pain, though data on these over-the-counter products are limited 5
Vaginal DHEA (prasterone) can be considered for vaginal dryness or pain with sexual activity, as several studies have shown it to be effective at reducing dyspareunia in postmenopausal individuals 1, 2
Ospemifene, an FDA-approved selective estrogen receptor modulator (SERM), effectively treats vaginal dryness and dyspareunia in postmenopausal women with vulvar and vaginal atrophy 1, 2
Pelvic floor physical therapy may help improve sexual pain, arousal, lubrication, orgasm, and satisfaction, particularly in women with associated pelvic floor dysfunction 1, 2

For women at age 83, the risk of breast cancer from topical estrogen therapy is minimal compared to the benefits for quality of life 1, 2
A large cohort study of almost 50,000 patients with breast cancer followed for up to 20 years showed no evidence of higher risk of breast cancer-specific mortality in those using vaginal estrogen 1

Start with topical vaginal estrogen (Premarin) as first-line therapy unless contraindicated 1, 2
If ineffective or not tolerated, consider vaginal DHEA or ospemifene 1, 2
Supplement with non-hormonal options like vaginal moisturizers and lubricants as needed 5
Consider referral for pelvic floor physical therapy if pain persists despite adequate treatment of vaginal atrophy 1

Inadequate follow-up: symptoms may require ongoing management and treatment adjustments over time 1
Focusing only on sexual symptoms: remember that urinary symptoms (urgency, recurrent UTIs) are also part of genitourinary syndrome of menopause and respond to estrogen therapy 3, 4

The National Comprehensive Cancer Network recommends evaluating the severity of specific symptoms, such as vaginal dryness, dyspareunia, and urinary symptoms, and reviewing the medical history to identify contraindications to hormonal therapy, including a history of estrogen-dependent cancers, abnormal vaginal bleeding, and active liver disease 6
A pelvic evaluation should be performed to assess vaginal atrophy, according to the National Comprehensive Cancer Network 6

The American College of Obstetricians and Gynecologists suggests that low-dose vaginal estrogen therapy may be considered with caution to manage genitourinary symptoms in breast cancer survivors, although individualized risk-benefit assessment is required 6
The use of low-dose vaginal estrogen was not associated with an increased risk of breast cancer-specific mortality in a large cohort study of nearly 50,000 breast cancer patients followed for up to 20 years, as reported by the Journal of the National Comprehensive Cancer Network 6

The National Comprehensive Cancer Network (NCCN) guidelines state that low‑dose vaginal estrogen is the most effective therapy for GSM, producing significant improvement in vaginal dryness, dyspareunia, itching, and urinary symptoms such as urgency and recurrent urinary‑tract infections【7】.

NCCN lists three approved delivery systems for local estrogen: vaginal creams, estradiol‑releasing vaginal rings, and vaginal suppositories/tablets【8】.

A large cohort study of ≈ 50,000 breast‑cancer patients followed for up to 20 years found no increase in breast‑cancer‑specific mortality among users of vaginal estrogen【7】.
The NCCN recommends that breast‑cancer survivors may consider low‑dose vaginal estrogen after an individualized risk‑benefit assessment and should obtain oncology consultation【8】.
In a prospective study of 76 hormone‑receptor‑positive survivors on aromatase inhibitors, intravaginal estradiol‑releasing rings were safe and improved vaginal atrophy and sexual function【7】.

Initial assessment: Perform a pelvic examination to grade vaginal atrophy and review contraindications (history of estrogen‑dependent malignancy, abnormal vaginal bleeding, active liver disease)【8】.
First‑line therapy: Initiate low‑dose vaginal estrogen (cream, ring, or suppository) as the primary intervention for GSM reversal【7】.

If estrogen is contraindicated:
- Vaginal DHEA (prasterone) can be used for dyspareunia【7】.
- Ospemifene (a SERM) is an option for women without a history of estrogen‑dependent cancer【7】.
- Non‑hormonal moisturizers and lubricants are also acceptable【7】.
Adjunctive measures:
- Pelvic‑floor physical therapy should be added when pain persists despite adequate estrogen treatment【7】.
- Vaginal dilators are recommended for patients with radiation‑induced vaginal stenosis【7】.

NCCN advises caution with vaginal DHEA in women receiving aromatase inhibitors because it raises circulating androgens that may interfere with inhibitor efficacy【7】.